Canine Arthritis Treatment Market Report 2026

The canine arthritis treatment market size has grown strongly in recent years. It will grow from $2.47 billion in 2025 to $2.6 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to growing prevalence of canine arthritis, rising awareness among pet owners, advancements in veterinary pharmaceuticals, increase in dog population, expansion of veterinary clinics and hospitals.

The canine arthritis treatment market size is expected to see steady growth in the next few years. It will grow to $3.13 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to development of targeted biologic therapies, increasing adoption of precision medicine in veterinary care, innovation in surgical techniques for joint repair, growth of online and retail veterinary pharmacies, rising investment in stem cell and prp research. Major trends in the forecast period include rising adoption of non-steroidal anti-inflammatory drugs (nsaids), increased use of joint supplements like glucosamine and chondroitin, growth in stem cell therapy and platelet-rich plasma (prp) treatments, expansion of minimally invasive surgical procedures for dogs, integration of physical therapy and cold laser therapy in arthritis management.

The increasing pet ownership rate is expected to drive the growth of the canine arthritis treatment market in the coming years. Pet ownership refers to the responsibility and care assumed by individuals or households to meet the needs, well-being, and companionship of domesticated animals kept primarily for pleasure rather than utility. Rising pet ownership is driven by factors such as lifestyle changes, pet humanization, and higher disposable incomes. Canine arthritis treatments are used by pet owners to manage and alleviate arthritis symptoms in dogs, aiming to improve quality of life and maintain mobility. For example, in April 2025, according to the Canadian Animal Health Institute, a Canada-based trade association, Canada was home to an estimated 7.2 million dogs and 8.2 million cats in 2024, making pets an integral part of over half of Canadian households. Therefore, the rising pet ownership rate is supporting growth in the canine arthritis treatment market.

Leading companies in this market are innovating treatments such as bedinvetmab injections to address canine joint health and mobility. Bedinvetmab, a monoclonal antibody injection targeting nerve growth factor (NGF) involved in pain, has gained FDA approval. For instance, in May 2023, Zoetis Inc. received FDA approval for Librela, the first monoclonal antibody for dogs, which inhibits canine NGF's biological activity related to pain regulation in osteoarthritis. Administered monthly via subcutaneous injection, Librela offers a convenient, long-term solution for managing canine osteoarthritis pain.

In September 2024, Zoetis, a US-based animal health company specializing in veterinary pain management solutions, partnered with the Arthritis Foundation to raise awareness about osteoarthritis (OA) in pets. This collaboration aims to support educational initiatives that help pet owners identify OA symptoms in dogs and cats, providing tools to improve early detection and manage OA-related pain effectively. The Arthritis Foundation is a US-based nonprofit organization dedicated to the prevention, control, and cure of America’s leading cause of disability.

Major companies operating in the canine arthritis treatment market are Merck & Co. Inc., Bayer AG, Eli Lilly and Company, Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Royal Canin SAS, Virbac Group, Ceva Sante Animale S.A., Hill's Pet Nutrition Inc., Vetoquinol SA, Norbrook Laboratories Limited, American Regent Inc., Thorne Healthtech Inc., VetStem Inc., Eltech K-Laser s.r.l., Liquid Health Inc, Nutri-Vet LLC, OrthoPets LLC, Rejuvenate Bio Inc.

North America was the largest region in the canine arthritis treatment market in 2025. Asia-Pacifica is expected to be the fastest-growing region in the forecast period. The regions covered in the canine arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the canine arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the canine arthritis treatment market by increasing the cost of imported veterinary drugs, surgical equipment, and advanced biologics, particularly affecting regions such as north america and europe. This has created challenges for veterinary clinics and online pharmacies that rely on imported products. On the positive side, tariffs have stimulated local production and development of cost-effective treatment alternatives, driving innovation and encouraging domestic pharmaceutical manufacturing.

The canine arthritis treatment market research report is one of a series of new reports that provides canine arthritis treatment market statistics, including canine arthritis treatment industry global market size, regional shares, competitors with a canine arthritis treatment market share, detailed canine arthritis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the canine arthritis treatment industry. This canine arthritis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Canine arthritis treatment involves various medical and therapeutic approaches aimed at addressing the chronic condition characterized by inflammation and progressive cartilage deterioration in a dog's joints. The goal is to reduce pain and inflammation, preserve joint function, and slow down disease progression.

The primary treatments for canine arthritis include drugs, supplements, surgical procedures, and other interventions. Canine arthritis drugs are medications specifically formulated to alleviate symptoms and manage arthritis in dogs. These drugs can be administered orally, parenterally (such as injections), or through other routes, targeting conditions such as osteoarthritis, rheumatoid arthritis, osteochondrosis, and traumatic arthritis. They are distributed through veterinary clinics, hospitals, retail pharmacies, and online platforms, catering to various end-users such as veterinary hospitals, drug stores, and e-commerce platforms.

The canine arthritis treatment market includes revenues earned by entities by providing services such as extracorporeal shockwave therapy (ESWT), acupuncture, and hyaluronic acid supplements. The market value includes the value of related goods sold by the service provider or included within the service offering. The canine arthritis treatment market also includes sales of gabapentin, adequan canine, and metacam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.